NCT05948982View on ClinicalTrials.gov

Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 30, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Decompensated Liver Cirrhosis
Interventions
BIOLOGICAL

Human Umbilical Cord Mesenchymal Stem Cells

The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.

All Listed Sponsors
lead

Asia Cell Therapeutics (Shanghai) Co., Ltd.

INDUSTRY

NCT05948982 - Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis | Biotech Hunter | Biotech Hunter